{"id":"https://openalex.org/W1994026326","doi":"https://doi.org/10.1158/1535-7163.targ-11-b74","title":"Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.","display_name":"Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.","publication_year":2011,"publication_date":"2011-11-01","ids":{"openalex":"https://openalex.org/W1994026326","doi":"https://doi.org/10.1158/1535-7163.targ-11-b74","mag":"1994026326"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-11-b74","doi":"https://doi.org/10.1158/1535-7163.targ-11-b74","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-b74","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035808651","display_name":"Andrew S. Moore","orcid":"https://orcid.org/0000-0001-8062-1779","observed_orcids":["https://orcid.org/0000-0001-8062-1779"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Moore","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087031667","display_name":"Amir Faisal","orcid":"https://orcid.org/0000-0002-7376-8286","observed_orcids":["https://orcid.org/0000-0002-7376-8286"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Amir Faisal","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036587927","display_name":"Vassilios Bavetsias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Vassilios Bavetsias","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102992861","display_name":"David Gonz\u00e1lez de Castro","orcid":"https://orcid.org/0000-0003-0580-5636","observed_orcids":["https://orcid.org/0000-0003-0580-5636"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Gonzalez de Castro","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chongbo Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Chongbo Sun","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050713768","display_name":"Butrus Atrash","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Butrus Atrash","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089603827","display_name":"Melanie R. Valenti","orcid":"https://orcid.org/0000-0001-7610-1375","observed_orcids":["https://orcid.org/0000-0001-7610-1375"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Melanie Valenti","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904367","display_name":"Alexis de Haven Brandon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alexis de Haven Brandon","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055603007","display_name":"Sian Avery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sian Avery","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052706160","display_name":"Andrew D.J. Pearson","orcid":"https://orcid.org/0000-0002-8738-5913","observed_orcids":["https://orcid.org/0000-0002-8738-5913"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Pearson","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003965204","display_name":"Paul Workman","orcid":"https://orcid.org/0000-0003-1659-3034","observed_orcids":["https://orcid.org/0000-0003-1659-3034"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Workman","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055979646","display_name":"Julian Blagg","orcid":"https://orcid.org/0000-0002-7409-0323","observed_orcids":["https://orcid.org/0000-0002-7409-0323"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Julian Blagg","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058014829","display_name":"Florence I. Raynaud","orcid":"https://orcid.org/0000-0003-0957-6279","observed_orcids":["https://orcid.org/0000-0003-0957-6279"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Florence Raynaud","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110523635","display_name":"Suzanne A. Eccles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Suzanne Eccles","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052675504","display_name":"Spiros Linardopoulos","orcid":"https://orcid.org/0000-0002-6600-400X","observed_orcids":["https://orcid.org/0000-0002-6600-400X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Spiros Linardopoulos","raw_affiliation_strings":["1Institute of Cancer Research, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Institute of Cancer Research, London, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I142947616"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"11_Supplement","first_page":"B74","last_page":"B74"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/flt3-inhibitor-resistance","display_name":"FLT3 inhibitor resistance","score":0.7329999804496765},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.8140000104904175},{"id":"https://openalex.org/keywords/flt3-tkd","display_name":"FLT3-TKD","score":0.7089999914169312},{"id":"https://openalex.org/keywords/flt3-ligand","display_name":"Flt3 ligand","score":0.718999981880188},{"id":"https://openalex.org/keywords/aurora-kinase-inhibition","display_name":"Aurora kinase inhibition","score":0.6669999957084656},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9100000262260437},{"id":"https://openalex.org/keywords/molm-13-cells","display_name":"MOLM-13 cells","score":0.8220000267028809},{"id":"https://openalex.org/keywords/survivin","display_name":"survivin","score":0.5950000286102295},{"id":"https://openalex.org/keywords/imidazo-4-5-b-pyridine","display_name":"imidazo[4,5-b]pyridine","score":0.8870000243186951}],"concepts":[{"id":"https://openalex.org/C2910954276","wikidata":"https://www.wikidata.org/wiki/Q14912399","display_name":"Fms-Like Tyrosine Kinase 3","level":4,"score":0.6797515153884888},{"id":"https://openalex.org/C20552341","wikidata":"https://www.wikidata.org/wiki/Q4822632","display_name":"Aurora inhibitor","level":4,"score":0.6631737947463989},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6202490329742432},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6177002191543579},{"id":"https://openalex.org/C2780808130","wikidata":"https://www.wikidata.org/wiki/Q24745285","display_name":"Aurora kinase","level":4,"score":0.5772545337677002},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.525839626789093},{"id":"https://openalex.org/C176944494","wikidata":"https://www.wikidata.org/wiki/Q1415380","display_name":"Point mutation","level":4,"score":0.5029475092887878},{"id":"https://openalex.org/C141937037","wikidata":"https://www.wikidata.org/wiki/Q14911664","display_name":"Aurora B kinase","level":5,"score":0.4282240569591522},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.4208183288574219},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3862779438495636},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35630691051483154},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.3556870222091675},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.3491005301475525},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.20553439855575562},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.17123648524284363},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.09787729382514954},{"id":"https://openalex.org/C85813293","wikidata":"https://www.wikidata.org/wiki/Q188909","display_name":"Cell division","level":3,"score":0.06984704732894897},{"id":"https://openalex.org/C47432576","wikidata":"https://www.wikidata.org/wiki/Q918594","display_name":"Spindle apparatus","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-11-b74","doi":"https://doi.org/10.1158/1535-7163.targ-11-b74","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-b74","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2979654295","https://openalex.org/W3193559035","https://openalex.org/W3015749894","https://openalex.org/W2042636485","https://openalex.org/W2011853681","https://openalex.org/W2249670160","https://openalex.org/W2955339485","https://openalex.org/W4282922160","https://openalex.org/W3149243933","https://openalex.org/W2261840010"],"abstract_inverted_index":{"Abstract":[0],"Internal":[1],"tandem":[2],"duplication":[3],"or":[4],"kinase":[5,13,22,147,382],"domain":[6],"point":[7,218],"mutations":[8,409],"of":[9,32,36,73,92,99,110,121,138,154,189,196,265,275,291,304,320,334,346,367,376,399,410,422],"the":[10,97,152,200,234,321,350,379,397,411,423],"fms-like":[11],"tyrosine":[12],"3":[14],"gene":[15],"(FLT3-ITD,":[16],"-TKD)":[17],"result":[18],"in":[19,30,47,65,118,125,151,178],"constitutive":[20],"FLT3":[21,52,61,74,94,161,175,190,202,256,305,368,377,412],"activation":[23],"and":[24,34,42,59,96,133,145,169,174,214,220,253,257,288,294,312,329,336,349,369,378,403,429],"promote":[25],"leukemic":[26],"proliferation.":[27],"FLT3-ITD":[28,179,213,323],"occurs":[29],"20\u201335%":[31],"adults":[33],"15%":[35],"children":[37],"with":[38,199,212,331,360,364],"acute":[39],"myeloid":[40],"leukemia":[41,126],"confers":[43],"a":[44,55,108,115,187,215,248,263,301,388],"poor":[45],"prognosis":[46],"both":[48],"age":[49],"groups.":[50],"Activated":[51],"therefore":[53],"represents":[54],"valid":[56],"therapeutic":[57],"target":[58],"several":[60,119],"inhibitors":[62,75,148],"are":[63,107,210,231,355],"currently":[64],"phase":[66],"II-III":[67],"clinical":[68,71],"trials.":[69],"The":[70],"impact":[72],"has":[76,141,281],"thus":[77],"far":[78],"been":[79,128,142],"limited":[80,129],"by":[81,193,384,395,407],"transient":[82],"responses":[83],"when":[84,270],"used":[85],"as":[86],"single":[87],"agents":[88],"due":[89],"to":[90,130,172,233,358],"lack":[91],"sustained":[93],"inhibition":[95,164,366,375],"emergence":[98],"secondary":[100,408],"acquired":[101],"resistance":[102,177,192,405],"following":[103],"treatment.":[104],"Aurora":[105,139,146,163,286,289,370,383],"kinases":[106,112,267],"family":[109],"serine-threonine":[111],"that":[113,159,226],"play":[114],"key":[116],"role":[117],"stages":[120],"mitosis.":[122],"Although":[123],"studies":[124],"have":[127,185],"cell":[131,326,352],"lines":[132,327],"small":[134],"patient":[135],"cohorts,":[136],"over-expression":[137],"A":[140,287],"consistently":[143],"demonstrated":[144],"show":[149],"potential":[150],"treatment":[153,195,390],"AML.":[155,181],"Our":[156],"hypothesis":[157],"is":[158,247],"simultaneous":[160],"/":[162],"will":[165],"improve":[166],"single-agent":[167],"efficacy":[168],"reduce":[170],"susceptibility":[171],"FLT3-ligand-driven":[173],"mutation-driven":[176],"positive":[180,324],"In":[182,277,314,340,372],"addition,":[183],"we":[184,224],"generated":[186],"model":[188],"inhibitor":[191,203,237,259],"prolonged":[194],"MOLM-13":[197,328],"cells":[198,230],"selective":[201,255],"MLN518.":[204],"These":[205],"resistant":[206],"cells,":[207],"termed":[208],"MOLM-13-RES,":[209,354],"doubly-mutated":[211,228,351],"FLT3-TKD":[216],"(D835Y)":[217],"mutation":[219],"over-express":[221],"Survivin.":[222],"Here":[223],"demonstrate":[225],"such":[227],"AML":[229,325,394],"sensitive":[232,357],"dual":[235,365,374],"FLT3-Aurora":[236],"CCT241736.":[238],"CCT241736,":[239,359],"an":[240],"imidazo[4,5-b]pyridine":[241],"derivative":[242],"discovered":[243],"at":[244,272],"our":[245],"Institution,":[246],"novel,":[249],"orally":[250],"bioavailable,":[251],"potent":[252],"highly":[254],"pan-Aurora":[258],"[S(10)":[260],"=":[261],"0.057;":[262],"fraction":[264],"386":[266],"inhibited":[268],">90%":[269],"screened":[271],"1":[273],"\u03bcM":[274,296],"CCT241736].":[276],"biochemical":[278],"assays,":[279,316],"CCT241736":[280,299,317,385],"IC50":[282],"values":[283,333],"against":[284],"FLT3,":[285],"B":[290],"0.035,":[292],"0.015":[293],"0.1":[295,335],"respectively.":[297,339],"Furthermore,":[298],"inhibits":[300,318],"wide":[302],"range":[303],"mutants,":[306],"including":[307],"FLT3-ITD,":[308],"-D835Y,":[309],"-D835H,":[310],"-K663Q":[311],"-N841I.":[313],"cellular":[315],"viability":[319],"human":[322],"MV-4;11":[330,348],"EC50":[332],"0.27":[337],"M":[338],"vivo,":[341],"mouse":[342],"tumor":[343],"xenograft":[344],"models":[345],"MOLM-13,":[347],"line,":[353],"also":[356],"biomarker":[361],"modulation":[362],"consistent":[363],"kinases.":[371],"summary,":[373],"critical":[380],"mitotic":[381],"may":[386],"represent":[387],"novel":[389],"strategy":[391],"for":[392],"FLT3-mutated":[393],"overcoming":[396],"effects":[398],"high":[400],"FL":[401],"levels":[402],"limiting":[404],"caused":[406],"gene.":[413],"Citation":[414],"Format:":[415],"{Authors}.":[416],"{Abstract":[417],"title}":[418],"[abstract].":[419],"In:":[420],"Proceedings":[421],"AACR-NCI-EORTC":[424],"International":[425],"Conference:":[426],"Molecular":[427],"Targets":[428],"Cancer":[430,442],"Therapeutics;":[431],"2011":[432],"Nov":[433],"12-16;":[434],"San":[435],"Francisco,":[436],"CA.":[437],"Philadelphia":[438],"(PA):":[439],"AACR;":[440],"Mol":[441],"Ther":[443],"2011;10(11":[444],"Suppl):Abstract":[445],"nr":[446],"B74.":[447]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2016-06-24T00:00:00"}